ArticleBone marrow transplantation2017
Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.
Open access · greenAbstract readMulticenter Study
In one paragraph
Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era.Clinical and experimental medicine · 2024Pooled it
- Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan.International journal of hematology · 2018Trial
- Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.European journal of haematology · 2026Article
- Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma.Scientific reports · 2025Article
- Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study.Therapeutic advances in medical oncology · 2025Article
- Racial and Ethnic Disparities in Autologous Hematopoietic Cell Transplantation Utilization in Multiple Myeloma Have Persisted Over Time Even After Referral to a Transplant Center.Transplantation and cellular therapy · 2024Article
- Current Status on Management of Primary Plasma Cell Leukemia.Current oncology reports · 2024Review
- Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group.Archives of medical science : AMS · 2024Article
- Review
- Autologous stem cell transplantation in multiple myeloma patients with renal impairment.Annals of hematology · 2023Article
- Article
- Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.Transplantation and cellular therapy · 2022Article
- Role of Stem Cell Transplantation in Multiple Myeloma.Cancers · 2021Review
- [Problems and progress of autologous hematopoietic stem cell transplantation in multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma.Leukemia & lymphoma · 2020Article
- How I manage frontline transplant-eligible multiple myeloma in Italy.Hematology reports · 2020Article
- Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma.Clinical hematology international · 2019Article
- Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease: Lessons Learned.Transplantation · 2019Article
- Current status of autologous stem cell transplantation for multiple myeloma.Blood cancer journal · 2019Review
- Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.Bone marrow transplantation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 20 institutions in 5 countries.
A MahindraUniversity of California San Francisco Medical Center, San Francisco, CA, USA.
P HariCIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
R FraserCIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
M FeiCIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
J HuangCIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
J BerdejaSarah Cannon BMT Program, Nashville, TN, USA.
N CallanderUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.
L CostaDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
M A DiazDepartment of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
C FreytesTexas Transplant Institute, San Antonio, TX, USA.
R P GaleHematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
S GirniusUniversity of Cincinnati, Cincinnati, OH, USA.
L HolmbergFred Hutchinson Cancer Research Center, Nashville, TN, USA.
M Kharfan-DabajaDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
S KumarMayo Clinic Rochester, Rochester, MN, USA.
R KyleMayo Clinic Rochester, Rochester, MN, USA.
H LazarusSeidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
C LeeRoyal Adelaide Hospital, Adelaide, SA, Australia.
A MaiolinoHospital Universitario Clementinio Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
J MorebDivision of Hematology & Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, FL, USA.
T NishihoriDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
A PawarodeBlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA.
A SaadDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
B N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
J SchriberCancer Transplant Institute, Virginia G. Piper Cancer Center, Scottsdale, AZ, USA.
B WilliamOhio State Medical Center, Columbus, OH, USA.
B M WirkDivision of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA, USA.
A KrishnanCity of Hope National medical Center, Duarte, CA, USA.
Y NietoDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
A D'SouzaCIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Medical College of Wisconsin · USMoffitt Cancer Center · USUniversity of Alabama at Birmingham · USArizona Oncology · USCHRISTUS Transplant Institute · USCity Of Hope National Medical Center · USFred Hutch Cancer Center · USHospital Infantil Universitario Niño Jesús · ESHospital Universitário Clementino Fraga Filho · BRImperial College London · GBMayo Clinic · USRoyal Adelaide Hospital · AUSarah Cannon · USSeattle Cancer Care Alliance · USThe University of Texas MD Anderson Cancer Center · USUniversity Hospitals Seidman Cancer Center · USUniversity of California San Francisco Medical Center · USUniversity of Cincinnati · USUniversity of Florida Health · USUniversity of Michigan–Ann Arbor · US
Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MClinical and Translational Science AwardUL1TR001436 · NCATS · MEDICAL COLLEGE OF WISCONSIN · PI FREED, JULIE K · 2015 to 2025
$47.5MEasy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8MInstitutional Career Development CoreKL2TR001438 · NCATS · MEDICAL COLLEGE OF WISCONSIN · PI WIDLANSKY, MICHAEL E · 2015 to 2024
$2.9MClinical and Translational Science AwardKL2TR000056 · NCATS · MEDICAL COLLEGE OF WISCONSIN · PI SHAKER, REZA NONE · 2012 to 2015
$609kNCATS NIH HHS KL2 TR000056NCATS NIH HHS KL2 TR001438NCATS NIH HHS UL1 TR001436NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294
Abstract
Autologous hematopoietic cell transplantation (AHCT) in multiple myeloma (MM) patients with renal insufficiency (RI) is controversial. Patients who underwent AHCT for MM between 2008 and 2013 were identified (N=1492) and grouped as normal/mild (⩾60 mL/min), N=1240, moderate (30-59), N=185 and severe RI (<30), N=67 based on Modification of Diet in Renal Disease. Multivariate analyses of non-relapse mortality (NRM), relapse, PFS and overall survival (OS) were performed. Of the 67 patients with severe RI, 35 were on dialysis prior to AHCT. Patients received melphalan 200 mg/m
Indexed as
AdultAgedFemaleHematopoietic Stem Cell TransplantationHumansMaleMelphalanMiddle AgedMultiple MyelomaMyeloablative AgonistsRenal InsufficiencySurvival AnalysisTransplantation, AutologousYoung AdultMelphalanMyeloablative Agonists
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.